Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: StemCells Inc

Market Cap 126M 109M 100M 94.26M 177M 11.92B 179M 1.19B 462M 5.85B 474M 464M 20.23B P/E 2026 *
-6.27x
P/E 2027 * -5.88x
Enterprise Value 126M 109M 100M 94.26M 177M 11.92B 179M 1.19B 462M 5.85B 474M 464M 20.23B EV / Sales 2026 *
36.6x
EV / Sales 2027 * 11.9x
Free-Float
100%
Yield 2026 *
-
Yield 2027 * -
Jun. 16 Microbot Medical Inc. Enters Into Agreement With Lovell Government Services To Expand Access For America?s Veteran And Military Patient Populations CI
Jun. 16 Microbot Medical Enters Agreement Expanding Access to Federal Healthcare Systems MT
Jun. 09 Microbot Medical Inc. Announces A Notable Health System as the First in Michigan to Adopt the Liberty Endovascular Robotic System CI
Jun. 02 Microbot Medical Inc. Secures First North Carolina Healthcare System to Adopt the LIBERTY Endovascular Robotic System CI
May. 26 Microbot Medical Inc. Receives Its First International Regulatory Approval for the Commercialization of the LIBERTY Endovascular Robotic System CI
May. 18 Microbot Medical Inc. - Shareholder/Analyst Call
May. 14 Microbot Medical recorded revenue during its quarter ended March 31, benefiting from limited market release of Liberty System RE
May. 13 Microbot Medical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
May. 05 Microbot Medical®'s Liberty® endovascular robotic system is now adopted by multiple accounts across key territories including two Access-PVI pivotal clinical trial sites RE
May. 05 Microbot Medical Inc Wins Accounts for Liberty Endovascular Robotic System Across Key Territories CI
Apr. 13 Microbot Medical Inc. Commences Full Market Release Of Liberty Endovascular Robotic System In The U.S CI
Mar. 26 Microbot Medical Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
Mar. 26 Emory Healthcare Successfully Completes Robotic Peripheral Endovascular Procedures using Microbot Medical®?s LIBERTY® Endovascular Robotic System CI
Manager TitleAgeSince
Chief Executive Officer 54 1988-08-01
Director of Finance/CFO 47 2022-03-31
Chief Operating Officer - 2025-01-20
Director TitleAgeSince
Chairman 54 2012-12-31
Director/Board Member 61 2016-11-27
Director/Board Member 65 2017-02-05
Change 5-day change 1-year change 3-year change Capi.($)
-0.93%-0.57%-12.58%-10.89% 43.44B
+0.76%+9.42%+303.09%+540.82% 33.54B
-4.74%-6.31%+10.75%-20.99% 28.48B
-0.47%-0.35%+3.38%+31.20% 29.2B
+0.06%+4.36%+13.31%+21.11% 25.34B
-0.02%+10.18% - - 14.36B
-0.98%-1.86%+53.43%+106.06% 13.05B
-1.22%-4.01%+2.08%+2.93% 12.67B
+1.67%+1.35%+105.56%+81.16% 12.28B
Average -0.66%+1.33%+59.88%+93.93% 23.6B
Weighted average by Cap. -0.81%+1.35%+62.53%+105.72%

Financials

2026 *2027 *
Net sales 3.45M 2.98M 2.74M 2.58M 4.84M 326M 4.88M 32.43M 12.62M 160M 12.95M 12.67M 553M 10.6M 9.14M 8.41M 7.91M 14.87M 1B 14.99M 99.63M 38.79M 491M 39.78M 38.93M 1.7B
Net income -20.45M -17.64M -16.22M -15.27M -28.69M -1.93B -28.93M -192M -74.83M -947M -76.75M -75.11M -3.28B -21.45M -18.5M -17.01M -16.01M -30.09M -2.02B -30.34M -202M -78.49M -994M -80.51M -78.79M -3.44B
Net Debt - -
Logo StemCells Inc
Microbot Medical Inc. is a pre-commercial stage medical technology company. It has developed the single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems. It specializes in the research, design and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, it is developing a fully disposable robot for various endovascular interventional procedures. The LIBERTY Endovascular Robotic Surgical System is designed to maneuver guidewires and over-the-wire devices (such as microcatheters) within the body’s vasculature. It eliminates the need for extensive capital equipment requiring dedicated Cath-lab rooms as well as dedicated staff. Its addressable markets for the LIBERTY Endovascular Robotic Surgical System include the peripheral interventional radiology, interventional cardiology and interventional neuroradiology markets.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!